Inventor
James C. Barrow
Inventor
Harleysville, PA, US
Overview
Patents· 42 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds36%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
A61KPreparations for medical, dental or toiletry purposes21%
C07KPeptides3%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
C11CFatty acids from fats, oils or waxes2%
Y02EReduction of greenhouse gas [ghg] emissions, related to energy generation, transmission or distribution2%
C07BGeneral methods of organic chemistry1%
C07CAcyclic or carbocyclic compounds1%
PatentTitleYear
11,001,581Compounds which inhibit RNA polymerase, compositions including such compounds, and their use202110,934,283COMT inhibiting methods and compositions202110,844,070Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system202010,479,790COMT inhibiting methods and compositions201910,415,065Enzymatic modification of oil201910,266,534Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system201910,035,799COMT inhibiting methods and compositions20189,951,057COMT inhibiting methods and compositions20189,885,068'Enzymatic modification of oil'20189,399,651'Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders'20169,309,199'Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders'20169,266,881'Triazolopyridinone PDE10 inhibitors'20169,260,413'Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders'20169,023,616'Oil producing microbes and method of modification thereof'20159,024,032'Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders'20158,987,310'Heterocycle amide T-type calcium channel antagonists'20158,969,364'Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders'20158,637,513'Heterocycle phenyl amide T-type calcium channel antagonists'20148,530,483'Substituted azabenzoxazoles'20138,501,773'4-fluoro-piperidine T-type calcium channel antagonists'20138,394,837'2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer\'s disease'20138,389,720'Quinolone neuropeptide S receptor antagonists'20138,263,627'Pyridyl amide T-type calcium channel antagonists'20128,114,887'Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer\'s disease'20128,003,653'Imidazolidinone compounds useful as β-secretase inhibitors for the treatment of Alzheimer\'s disease'20117,968,571'2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer\'s Disease'20117,875,636'Pyridyl amide T-type calcium channel antagonists'20117,847,100'1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer\'s disease'20107,745,452'Quinazolinone T-type calcium channel antagonists'20107,550,481'Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer\'s disease'20097,144,899'Thrombin inhibitors'20067,084,134'Thrombin inhibitors'20066,610,701'Thrombin inhibitors'20036,544,982'Thrombin receptor antagonists'20036,534,510'Thrombin inhibitors'20036,515,023'Thrombin receptor antagonists'20036,515,011'Thrombin inhibitors'20036,462,050'Thrombin inhibitors'20026,403,612'Thrombin receptor antagonists'20026,387,911'Pyrazinone thrombin inhibitors'20026,339,090'Alpha 1A adrenergic receptor antagonists'20026,235,759'Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists'2001Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2001–2009Patents assigned to MERCK & CO INC (13)· patent assignee history
2001–2016Based in Harleysville, PA, US· patent location history
2010–2016Patents assigned to MERCK SHARP & DOHME (18)· patent assignee history
2011–2021Based in Arnold, MD, US· patent location history
2012–2016Patents assigned to BARROW JAMES C (10)· patent assignee history
2015–2019Based in Torquay, AU· patent location history
2018–2021Patents assigned to LIEBER INST FOR BRAIN DEVELOPMENT (4)· patent assignee history
2019–2021Patents assigned to LIEBER INST INC (4)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MERCK SHARP & DOHME | 18 | 2010–2016 |
| MERCK & CO INC | 13 | 2001–2009 |
| BARROW JAMES Cself | 10 | 2012–2016 |
| LIEBER INST FOR BRAIN DEVELOPMENT | 4 | 2018–2021 |
| LIEBER INST INC | 4 | 2019–2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| Harleysville, Pennsylvania, US | 23 | 2001–2016 |
| Arnold, Maryland, US | 16 | 2011–2021 |
| Torquay, AU | 3 | 2015–2019 |